Extensive myelitis associated with anti-NMDA receptor antibodies

  • Olivier Outteryck1Email author,

    Affiliated with

    • Guillaume Baille1,

      Affiliated with

      • Jérôme Hodel2,

        Affiliated with

        • Marianne Giroux1,

          Affiliated with

          • Arnaud Lacour1,

            Affiliated with

            • Jérôme Honnorat3, 4, 5,

              Affiliated with

              • Hélène Zéphir1 and

                Affiliated with

                • Patrick Vermersch1

                  Affiliated with

                  BMC Neurology201313:211

                  DOI: 10.1186/1471-2377-13-211

                  Received: 8 October 2013

                  Accepted: 18 December 2013

                  Published: 27 December 2013

                  Abstract

                  Background

                  Encephalitis with anti-N-methyl-D-aspartate receptor antibodies (anti-NMDAR-Ab) is a rapid-onset encephalitis including psychosis, seizures, various movement disorders and autonomic system disturbances.

                  Case presentation

                  We report a very unusual case of extensive myelitis associated with anti-NMDAR-Ab. MRI also revealed a hyperintense T2 lesion, non-suggestive of MS, which progressively extended, associated with periventricular gadolinium enhancement visualized on brain MRI. Ophthalmological evaluation showed subclinical right optic neuritis. The absence of anti-AQP4 antibody argued against neuromyelitis optica spectrum disorder. A slight psychomotor slowing prompted us to search for various causes of autoimmune encephalitis. Anti-NMDAR-Ab was found in cerebrospinal fluid.

                  Conclusion

                  In patients with extensive myelitis who are seronegative for anti-AQP4 antibodies, and after other classical causes have been excluded, the hypothesis of atypical anti-NMDAR-Ab encephalitis should also be considered.

                  Keywords

                  Myelitis Anti-NMDAR antibodies Encephalitis Neuromyelitis optica

                  Background

                  Encephalitis with anti-N-methyl-D-aspartate receptor antibodies (anti-NMDAR-Ab) is a rapid-onset encephalitis including psychosis, seizures, various movement disorders and autonomic system disturbances. The physiopathology is based on immune-mediated neuronal dysfunction [1, 2]. We report the case of a 65-year-old woman presenting an extensive myelitis associated with anti-NMDAR-Ab.

                  Case presentation

                  A 65-year-old woman was admitted because of progressive paraparesis (June 2012). Six months before admission, she had presented with fever, chills, abdominal pain and unusual headache for one week with spontaneous recovery. Abdomen and brain MRI were normal at that time. Two months before admission, she described a progressive onset of walking difficulties. At the same time, constipation and dysuria were noted. At her admission, neurological examination noted walking difficulties related to moderate paraparesis, moderate superficial and deep sensory dysfunction of the lower limbs and urinary retention. A very slight dysfunction of mental processing without speech disturbance was noted and confirmed by her family. No seizures, dyskinesia, movement disorders, psychiatric symptoms or autonomic dysfunction were observed.

                  Spinal cord MRI showed longitudinally extensive myelitis from C5 to T10 with gadolinium (Gd) enhancement (Figure  1A,B). Brain MRI follow-up showed T2 hyperintensities within the insular regions, medial temporal lobes and thalamus (Figure  1C), associated with gadolinium enhancement of the meninges and ventricles (Figure  1D). Analysis of the cerebrospinal fluid (CSF) showed moderate lymphocytic pleocytosis (53 cells/mm3), mild increased protein concentration (0.91 g/L) and oligoclonal bands. PCR assays for herpesviridae in CSF were all negative. Ophthalmological examination showed delayed P100 latencies on the right side on visual evoked potentials and asymmetric global retinal nerve fibre layer (RNFL) thicknesses on optical coherence tomography (OCT) suggestive of asymptomatic right optic neuritis (ON). OCT analyses were both perfectly centred on the optic nerve head (Figure  1E). Tests for anti-aquaporin 4 (AQP4) antibodies (Ab) in serum were negative. EEG showed slow and discontinuous activity in the left fronto-temporal regions. Extensive tests for auto-Ab (anti-onconeuronal, anti-DNA, anti-phospholipid, anti-voltage-gated potassium channel, anti-glutamate acid decarboxylase) were negative except for anti-NMDAR-Ab (IgG isotype) in the CSF and serum. No cancer was found (gynaecological examination, pelvic ultrasonography and MRI, mammography, total-body computed tomography scan and positron emission tomography scan were all normal).
                  http://static-content.springer.com/image/art%3A10.1186%2F1471-2377-13-211/MediaObjects/12883_2013_929_Fig1_HTML.jpg
                  Figure 1

                  Spinal cord, brain and optical imaging follow-up of the patient. June 2012: Spinal cord magnetic resonance imaging (MRI) showing extensive hyper intense T2 lesion between C5 and T10 (A) with gadolinium enhancement on T1 sequence (B). Brain MRI showing multiple hyperintense T2 lesions on insular regions, medial temporal lobes and thalamus (C), but also gadolinium enhancement of ventricles and meninges (D). Peripapillary optical coherence tomography showing asymmetric retinal nerve fiber layer (E). July 2012: Control brain MRI showing extension of hyperT2 lesion load (F).

                  Intravenous corticosteroids (1 g per day during 3 days plus 5 days) were given but the paraparesis worsened (bedridden patient). Brain and spinal cord MRIs follow-up (July 2012) showed an extension of T2 lesions without Gd enhancement (Figure  1F) and a stable extensive T2 lesion without Gd enhancement, respectively. As soon as anti-NMDAR-Ab were detected, plasma exchanges (PLEX) were initiated and followed by intravenous rituximab (375 mg/m2 every week for 4 weeks) plus tapering oral corticosteroids (1 mg/kg). Brain and spinal cord MRIs follow-up (August 2012) showed the disappearance of the extensive spinal cord T2 lesion and stable cerebral T2 lesions. Biological follow-up of anti-NMDAR-Ab rates in CSF and serum was performed (Table  1). CSF analysis was weakly positive just after corticosteroids/PLEX (M1) and was negative 2 months after rituximab (M3). Serum analysis was less correlated to clinical status. Four months after the inaugural myelitis, there was a significant improvement of the paraparesis (the patient was able to walk for 5 metres with bilateral support) and a total regression of the slight psychomotor retardation was observed. Unfortunately, the patient presented rapidly evolving pneumocystis pneumonia at this time and she died of respiratory failure. Autopsy was not performed.
                  Table 1

                  Anti-NMDA-R follow-up of the titration in CSF and in serum (qualitative and quantitative)

                  Date

                  Jun 23rd

                  Jul 2nd

                  Jul 10th

                  Jul 11th

                  Jul 14th

                  Jul 16th

                  Jul 17th

                  Jul 23rd

                  Jul 30th

                  Aug 6th

                  Aug 13th

                  Oct 17th

                  CSF

                  + (1/10)

                  + (low)

                  NA

                  NA

                  NA

                  NA

                  -

                  NA

                  NA

                  NA

                  NA

                  -

                  Anti-NMDA-R in serum

                  NA

                  NA

                  + (1/10)

                  + (1/10)

                  -

                  + (low)

                  -

                  -

                  + (low)

                  NA

                  + (1/10)

                  -

                  Methylprednisolone (1 g/day IV)

                  3 days

                   

                  5 days

                           

                  PLEX

                    

                  Yes

                  Yes

                  Yes

                  Yes

                  Yes

                       

                  Rituximab (375 mg/m2/week during 4 weeks)

                         

                  Yes

                  Yes

                  Yes

                  Yes

                   

                  Jun, June; Jul, July; Aug, August; Oct, October; CSF, cerebrospinal fluid; NA, not available; PLEX, plasma exchange; 5 PLEX were performed followed by infusions of rituximab (375 mg/m2/week during 4 weeks).

                  Discussion

                  Our patient presented extensive myelitis associated with anti-NMDAR-Ab leading us to discuss a possible atypical form of anti-NMDAR-Ab encephalitis. Spinal cord symptoms were prominent throughout the clinical stage and were consistent with the extensive myelitis detected on spinal cord MRI. Slight psychomotor retardation is not sufficient to affirm that our patient presented anti-NMDAR-Ab encephalitis but early treatment might have stopped its development. Brain MRI showed hyperintense T2 lesions but also ventriculitis aspect. In view of the combination of extensive myelitis, brain T2 lesions non-suggestive of MS, ventriculitis aspect on MRI and subclinical ON, our first hypothesis was myelitis as a first event of neuromyelitis optica (NMO) or NMO spectrum disorder (NMOSD). Although cognitive disturbances are described in NMO [3], we also looked for other conditions involving auto-immune encephalitis and found anti-NMDAR-Ab in the CSF before immunosuppressive drugs had been applied.

                  Prodromal symptoms such as headache and fever are common [1] but we noted 3 atypical events for the hypothesis of anti-NMDAR-Ab encephalitis. First, myelitis is a very rare manifestation during anti-NMDAR-Ab encephalitis but has already been described [46]. In these 3 previous cases, all patients presented severe psychiatric or behavioural symptoms before the spinal cord syndrome and the encephalopathic symptoms remained prominent during all stages of the disease. In our case, the spinal cord syndrome remained prominent from the beginning and extension of the hyperintense T2 lesion was greater. Secondly, we highlighted in our case ventriculitis associated with meningeal Gd enhancement. Meningeal contrast enhancement in anti-NMDAR-Ab encephalitis is rare and [7, 8], to the best of our knowledge, the ventriculitis aspect has never previously been described. NMDA receptors are membrane receptors widely expressed in the central nervous system on various cells such as neurons, oligodendrocytes but also astrocytes [9]. The ependymal regions contain ependymal cells and astrocytes rich in AQP4, and can also be involved in NMO, as described in 2 previously reported cases with thin ependymal and periventricular Gd enhancement [10, 11]. Thirdly, our patient presented right subclinical ON. Since the prodromal symptoms dated back 6 months, it seems likely that the demyelinating pathology had already started 6 months before the spinal cord syndrome. RNFL atrophy most often (>94 %) appears within the 6 months after ON [12]. ON has only once been reported as a neurological manifestation of anti-NMDAR-Ab encephalitis [13].

                  Even though some correlations have been found between clinical status and anti-NMDAR-Ab titres in CSF, there is no reported correlation with anti-NMDAR-Ab titres in serum, and we therefore do not recommend a follow-up of anti-NMDAR-Ab titres in serum [1, 14].

                  Anti-NMDAR-Ab encephalitis has been described following massive brain damage induced by herpes simplex encephalitis (HSE) [15, 16]. Anti-NMDAR-Ab has also been found in sera of systemic lupus erythematosus and might be predictive of neuropsychiatric manifestations [17]. In the present case report, we cannot affirm that our patient presented anti-NMDAR-Ab encephalitis because of encephalopathic symptoms lacking and also cannot exclude that a massive brain and spinal damage of unknown etiology has led to secondary immunological response with anti-NMDA-R Ab production.

                  We can also discuss the hypothesis that our patient may have presented 2 auto-immune diseases concurrently: an NMOSD and an anti-NMDAR-Ab encephalitis. These are both Ab-mediated diseases and a comorbid association of auto-immune diseases is possible. Recently a case of NMO (seropositive anti-AQP4 Ab) following anti-NMDAR-Ab encephalitis has been described [18]. As our patient was seronegative for anti-AQP4 Ab and presented only subclinical ON, we cannot conclusively confirm or rule out this hypothesis.

                  Conclusion

                  In patients with extensive myelitis who are seronegative for anti-AQP4 Ab, and after other classical causes have been excluded, the hypothesis of atypical anti-NMDAR-Ab encephalitis should also be considered.

                  Consent

                  Written informed consent was obtained from the husband of the patient for publication of this Case report and the accompanying images. A copy of the written consent is available for review by the editor of this journal.

                  Declarations

                  Authors’ Affiliations

                  (1)
                  Department of Neurology, EA2686, Université Lille Nord de France
                  (2)
                  Department of Neuroradiology, Université Lille Nord de France
                  (3)
                  French Reference Centre for Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon, Hôpital Neurologique
                  (4)
                  Lyon Neuroscience Research Center INSERM U1028/CNRS UMR 5292
                  (5)
                  Université de Lyon, Université Claude Bernard Lyon 1

                  References

                  1. Dalmau J, Lancaster E, Martinez-Hernandez E, et al.: Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011, 10:63–74.PubMed CentralPubMedView Article
                  2. Misakova L, De Rossi P, Bouchet D, et al.: Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain 2012, 135:1606–1621.View Article
                  3. Blanc F, Zéphir H, Lebrun C, et al.: Cognitive functions in neuromyelitis optica. Arch Neurol 2008, 65:84–88.PubMed
                  4. Taylor RB, Mason W, Kong K, et al.: Reversible paraneoplastic encephalomyelitis associated with a benign ovarian teratoma. Can J neurol Sci 1999, 26:317–320.PubMed
                  5. Kruer MC, Koch TK, Bourdette DN, et al.: NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology 2010, 74:1473–1475.PubMedView Article
                  6. Lekoubou A, Viaccoz A, Didelot A, et al.: Anti-N-methyl-D-aspartate receptor encephalitis with acute disseminated encephalomyelitis-like MRI features. Eur J Neurol 2012, 19:e16-e17.PubMedView Article
                  7. Dalmau J, Tüzün E, Wu HY, et al.: Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007, 61:25–36.PubMed CentralPubMedView Article
                  8. Dalmau J, Gleichman AJ, Hughes EG, et al.: Anti-NMDA-receptor encephalitis: case series and analysis of the effect of antibodies. Lancet Neurol 2008, 7:1091–1098.PubMed CentralPubMedView Article
                  9. Paoletti P, Bellone C, Zhou Q: NMDA receptor subunit diversity: impact on receptor properties synaptic plasticity and disease. Nat Rev Neurosci 2013, 14:383–400.PubMedView Article
                  10. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al.: Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006, 63:964–968.PubMedView Article
                  11. Banker P, Sonni S, Kister I, et al.: Pencil-thin ependymal enhancement in neuromyelitis optica spectrum disorders. Mult Scler 2012, 18:1050–1053.PubMedView Article
                  12. Costello F, Coupland S, Hodge W, et al.: Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006, 59:963–969.PubMedView Article
                  13. Ishikawa N, Tajima G, Hyodo S, et al.: Detection of autoantibodies against NMDA-type glutamate receptor in a patient with recurrent optic neuritis and transient cerebral lesions. Neuropediatrics 2007, 38:257–260.PubMedView Article
                  14. Frechette ES, Zhou L, Galetta SL, et al.: Prolonged follow-up and CSF antibody titers in a patient with anti-NMDA receptor encephalitis. Neurology 2011, 76:S64-S66.PubMedView Article
                  15. Pruss H, Finke C, Höltje M, Hofmann J, Klingbeil C, Probst C, Borowski K, Ahnert-Hilger G, Harms L, Scwab JM, Ploner CJ, Koromowski L, Stoecker W, Dalmau J, Wandiger KP: N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012, 72:902–911.PubMed CentralPubMedView Article
                  16. Armangue T, Leypoldt F, Málaga I, Raspall-Chaure M, Marti I, Nichter C, et al.: Herpes Simplex Virus Encephalitis is a Trigger of Brain Autoimmunity. Ann Neurol 2013. doi:10.1002/ana.24083. epub ahead of print
                  17. Gono T, Kawaguchi Y, Kaneko H, Nishimura K, Hanaoka M, Kataoka S, et al.: Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus. Rheumatology 2011, 50:1578–1585.PubMedView Article
                  18. Zoccarato M, Saddi MV, Serra G, Pelizza MF, Rosellini I, Peddone L, Ticca A, Giometto B, Zuliani L: Aquaporin-4 antibody neuromyelitis optica following anti-NMDA receptor encephalitis. J Neurol 2013, 260:3185–3187.PubMedView Article
                  19. Pre-publication history

                    1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-2377/​13/​211/​prepub

                  Copyright

                  © Outteryck et al.; licensee BioMed Central Ltd. 2013

                  This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.